RBC Capital maintains Sector Perform on Biohaven, raises price target to $22

RBC Capital maintains Sector Perform rating on Biohaven. Price target raised from $19 to $22. Analyst Leonid Timashev issued the update. Rating status remains unchanged despite higher target.

Biohaven shares rise 31% as FDA sets 2027 review date for rare disease drug

FDA accepted Biohaven's NDA resubmission for Vyglxia with a Q1 2027 user fee goal date. Shares rose 31.36% to $15.43 on Thursday amid high trading volume. FDA plans to convene an advisory committee meeting for external stakeholder input. Partial clinical hold remains on BHV-7000 program due to nonclinical metabolite findings.

Biohaven secures up to $100 million from Ono for Asian IgG license

Biohaven enters exclusive licensing agreement with Ono Pharmaceutical for Japan, South Korea, Taiwan, and ASEAN regions. Secures up to $100 million in near-term payments, including $80 million upfront at closing. Earns approximately 20% royalties on net sales of licensed products in the territory. Deal covers lead asset BHV-1300 and next-generation degraders BHV-1310 and BHV-1320.

Biohaven faces FDA hold on BHV-7000 enrollment; lawsuit investigation launched

FDA pauses new enrollment in Biohaven's BHV-7000 trials due to insufficient rodent metabolite data. Dosing continues for over 600 randomized patients; pivotal study BHV7000-303 timeline remains intact. Shares fell 14.73% following the disclosure, triggering a securities investigation by Levi & Korsinsky. Company recently secured a $795 million licensing deal with SK Biopharmaceuticals for the Kv7 platform.

Biohaven stock rises 13% after securing $795 million SK Bio deal

Biohaven signed a global licensing deal with SK Biopharmaceuticals for its Kv7 platform, potentially worth up to $795 million. The deal includes $350 million in upfront cash and $50 million in 2027, with SK funding all future program costs. A Delaware federal court awarded Biohaven and Yale $4 million in a trade-secret dispute against Avilar Therapeutics. William Blair maintained a Market Perform rating, citing the need for more controlled clinical data.

Biohaven signs $795m Kv7 platform deal with SK Biopharmaceuticals

Biohaven signs global licensing deal with SK Biopharmaceuticals for its Kv7 platform. Total deal value reaches up to $795 million in upfront and milestone payments. Biohaven receives $400 million in near-term cash consideration. Deal includes tiered royalties ranging from mid-teens to low twenties on U.S. sales.